Biomobie is a regenerative medical organization with a number of bio-power "noninvasive vascular normalization" global patents. Its IT research and development centers and product design centers are located in Silicon Valley, USA. The medical research and development base is located in Boston, USA. The product application and production base is located in China Shanghai.
Biomobie took the lead in successfully developed the world's first group of non-invasive vascular regeneration patented technology "Bermudi bio-electric" technology, the birth of the technology broke through the vascular microcirculation damage difficult to repair the medical problems. "Circulatory disorders will cause the body's 414 kinds of diseases and 33 kinds of malignant tumors, he is the source of all diseases. Human microcirculation is good, 95% of the disease can be dead and more." Bermudian after thousands of cases of clinical validation confirmed, Repair human vascular microcirculation can achieve the purpose of recovering a variety of chronic diseases at the same time.
"Biomobie bio-electricity" technology 2 years since the experience of thousands of patients with noninvasive vascular regeneration course, the statistics show that a dozen chronic diseases and even some of the disease can not save the slow disease can also be passed Vascular regeneration to achieve the "incurable and more" purpose. This disruptive human vascular regeneration technique will have a profound impact on prolonging human life, reducing the probability of hospitalization, and future health care programs; adding an extremely safe and effective solution to the prevention and treatment of chronic diseases.
"Biomobie Biotechnology" technology for non-invasive repair of vascular disease applications in the field of hypertension prevention and control of the Shanghai Food and Drug Administration (SFDA) of the second class of medical equipment market access. In the post-clinical study found that the technology for heart disease, stroke, diabetic foot, varicose veins, male dysfunction and insomnia and other symptoms have a unique performance, further clinical trials have been in the United States Harvard University affiliated Braggen Hospital and the United States Mayo Hospital. The technology is expected to become a new vaccine for the prevention and treatment of vascular disease after the new treatment.
Biomobie Bio-Regeneration Factor Library and Bioelectronics Library are made up of dozens of electronic recipes, and the Bermudy R7 BBT-I, which contributes to the regeneration of endothelial progenitor cells, is just one of them. The World Health Organization predicts that the next century will be a preventive medicine-based health care system. Bermudy R7's two major factor libraries will become a new life prevention medical system after Western medicine and Chinese medicine. This system represents advanced preventive medicine. It is through the help of organ tissue cells to restore growth, regulate the activity of cells and metabolic levels, thereby promoting a variety of chronic diseases themselves, called the future of Chaoyang Medical. Bermudy R7 R & D success, is the field of human regenerative medicine a subversive breakthrough, will become an important milestone in the history of human life medicine.